Regional nodal irradiation might not improve locoregional recurrence-free survival in ypN0 breast cancer patients undergoing neoadjuvant chemotherapy

Background The role of regional nodal irradiation (RNI) after neoadjuvant chemotherapy (NAC) in patients with clinically node-positive (cN1) breast cancer remains controversial among those achieving nodal pathological complete response (ypN0). This multicenter study evaluated the impact of adjuvant RNI on survival outcomes in a real-world cohort. Methods Patients with invasive breast cancer and clinically positive axillary nodes treated with NAC were identified and categorized according to receipt of adjuvant RNI. Propensity score matching (1:1) was performed to balance baseline characteristics. Primary endpoints were 5-yr axillary recurrence-free survival (ARFS) and 5-yr locoregional recurrence-free survival (LRRFS). Results After propensity score matching, 842 patients (421 per group) were analyzed. RNI was not associated with improved 5-yr ARFS (94.9% vs. 95.8%, p=0.546) or 5-yr LRRFS (95.2% vs. 95.6%, p=0.977) when compared to no RNI. Disease-free (p=0.0003) and distant metastases-free (p=0.0002) survival rates were lower with RNI than without RNI, suggesting that patients undergoing RNI were affected by a worst disease. Multivariable analysis confirmed that RNI was not independently associated with ARFS or LRRFS, whereas residual nodal disease (ypN+) was the strongest predictor of poorer ARFS (HR 3.28, p=0.02) and LRRFS (HR 4.21, p=0.008). Conclusions Adjuvant RNI might not improve axillary or locoregional outcomes after NAC in cN+ breast cancer patients, particularly among those achieving ypN0 status. Post-treatment nodal status is strongly associated to locoregional prognosis, supporting consideration of RNI de-escalation in selected ypN0 patients.

Authors

Institutions

Publication Details

Journal
The Breast
Published
2026-11-19
DOI
https://doi.org/10.1016/j.breast.2026.104965
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Regional nodal irradiation might not improve locoregional recurrence-free survival in ypN0 breast cancer patients undergoing neoadjuvant chemotherapy

Marta Sevieri, Chiara Annunziata Pasqualina Anghelone, Chiara Listorti, Giulia Armatura et al.
The Breast
Breast Cancer Treatment Studies
article

Regional nodal irradiation might not improve locoregional recurrence-free survival in ypN0 breast cancer patients undergoing neoadjuvant chemotherapy

Marta Sevieri, Chiara Annunziata Pasqualina Anghelone, Chiara Listorti, Giulia Armatura, Daniela Bossi, Annalisa Curcio, Marco Lunghi, Secondo Folli, Simona Papi, Andrea Papadia, Valentina Zanella, Maria Luisa Gasparri, Fabio Corsi, Daniela Tognali, Sara Albasini, Anna Pertusati, Paola Canino, Luca Sorrentino, Francesca Angela Rovera, Stefano Mancini, Angelica Della Valle, Corrado Chiappa, Silvia Segattini, Giulia Pappalettera, Carlo Morasso, Beatrice Bignami, Seyedeh Negin Sadat Madarshahi, Christoph Mayr
article en

Abstract

Background The role of regional nodal irradiation (RNI) after neoadjuvant chemotherapy (NAC) in patients with clinically node-positive (cN1) breast cancer remains controversial among those achieving nodal pathological complete response (ypN0). This multicenter study evaluated the impact of adjuvant RNI on survival outcomes in a real-world cohort. Methods Patients with invasive breast cancer and clinically positive axillary nodes treated with NAC were identified and categorized according to receipt of adjuvant RNI. Propensity score matching (1:1) was performed to balance baseline characteristics. Primary endpoints were 5-yr axillary recurrence-free survival (ARFS) and 5-yr locoregional recurrence-free survival (LRRFS). Results After propensity score matching, 842 patients (421 per group) were analyzed. RNI was not associated with improved 5-yr ARFS (94.9% vs. 95.8%, p=0.546) or 5-yr LRRFS (95.2% vs. 95.6%, p=0.977) when compared to no RNI. Disease-free (p=0.0003) and distant metastases-free (p=0.0002) survival rates were lower with RNI than without RNI, suggesting that patients undergoing RNI were affected by a worst disease. Multivariable analysis confirmed that RNI was not independently associated with ARFS or LRRFS, whereas residual nodal disease (ypN+) was the strongest predictor of poorer ARFS (HR 3.28, p=0.02) and LRRFS (HR 4.21, p=0.008). Conclusions Adjuvant RNI might not improve axillary or locoregional outcomes after NAC in cN+ breast cancer patients, particularly among those achieving ypN0 status. Post-treatment nodal status is strongly associated to locoregional prognosis, supporting consideration of RNI de-escalation in selected ypN0 patients.

The BreastVol. 91
University of Insubria (IT), University of Milan (IT), Ospedale regionale di Lugano (CH), Ospedale di Bolzano (IT), Istituti Clinici Scientifici Maugeri (IT), Azienda Unità Sanitaria Locale Della Romagna (IT), Azienda Ospedaliero-Universitaria di Modena (IT), Ospedale “M. Bufalini” di Cesena (IT), Ospedale G.B. Morgagni - L.Pierantoni (IT), Policlinico San Matteo Fondazione (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), ASST Fatebenefratelli Sacco (IT), Aziende Socio Sanitarie Territoriale dei Sette Laghi (IT), Istituto Oncologico della Svizzera Italiana (CH), Azienda Sanitaria dell'Alto Adige (IT), Università della Svizzera italiana (CH)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon